

Emicizumab Use in Pediatric Patients in the Real World: an Analysis of the PedNet Registry

First published: 27/11/2019

Last updated: 25/06/2024

Study

Ongoing

Administrative details

PURI

<https://redirect.ema.europa.eu/resource/48526>

EU PAS number

EUPAS31954

Study ID

48526

DARWIN EU® study

No

Study countries

Austria
Belgium
Canada
Czechia
Denmark
Finland
France
Germany
Greece
Ireland
Israel
Italy
Netherlands

Norway
Portugal
Spain
Sweden
Switzerland
United Kingdom

Study description

The main aim of this non-interventional, secondary data use Post-Authorization Safety Study (PASS) is to assess safety of emicizumab use in children with haemophilia A during routine clinical care, among pediatric patients enrolled in the European Pediatric Network for Haemophilia Management (PedNet) Registry. PedNet Registry is the largest registry in the world for pediatric patients with haemophilia, currently, 20 countries with approximately 32 treatment centers participate. The registry includes all age groups and severities (FVIII <25%), which includes substantial coverage and an adequate representation of the pediatric patient population. The primary safety events of interest in this study are thromboembolic events (TEs), thrombotic microangiopathy (TMA), and anaphylaxis. However, all safety events collected in the PedNet Registry will be reported. In addition to safety, effectiveness of emicizumab will be evaluated by the annual bleeding rate, as reported in the PedNet Registry. The following criteria describe the population eligible for this study, which will be a subset of the overall population participating in the PedNet Registry.

Inclusion criteria for inclusion in the PedNet Registry:

- Diagnosis of haemophilia A
- Factor VIII activity <25%
- Treated in one of the participating centers.

Additional inclusion for emicizumab-specific analysis:

- Received prophylactic treatment with emicizumab.

Exclusion criteria for the PedNet Registry:

- Referral to a participating center after development of inhibitors
- Informed consent for participation in the PedNet Registry not obtained.

Exclusion criteria for emicizumab-specific analysis:

- Inherited or acquired bleeding disorder other than haemophilia A.

The PedNet Registry will extract data indicated in this protocol, perform the statistical analysis, and provide results to the Marketing Authorization Holder (MAH) who will generate an annual PASS report and/or include the results in the PBRER.

Study status

Ongoing

Research institution and networks

Institutions

F. Hoffmann-La Roche

First published: 01/02/2024

Last updated 01/02/2024

Institution

Contact details

Study institution contact

Letizia Polito

Study contact

global.clinical_trial_registry@roche.com

Primary lead investigator

Letizia Polito

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

24/03/2019

Study start date

Planned:

30/11/2019

Actual:

03/12/2019

Date of final study report

Planned:

30/09/2025

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

F. Hoffmann-La Roche, Ltd.

Study protocol

[Prot MO40685 \(PEDNET\) emicizumab v1_Redacted.pdf](#)(593.4 KB)

[MO40685 \(PEDNET\)-Protocol v2_Redacted.pdf](#)(284.5 KB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Other study registration identification numbers and links

MO40685, NCT02979119

[PedNet Registry](#)

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition
Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness
Effectiveness study (incl. comparative)
Safety study (incl. comparative)

Data collection methods:

Secondary data collection

Main study objective:

The primary objective for this study is to evaluate the overall safety and tolerability of emicizumab administration in all paediatric patients with haemophilia A in real-world conditions, and in subgroups determined by age and inhibitor status, as well as by severity for patients without inhibitors

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Name of medicine

Hemlibra

Study drug International non-proprietary name (INN) or common name

EMICIZUMAB

Anatomical Therapeutic Chemical (ATC) code

(B02BX06) emicizumab

Medical condition to be studied

Haemophilia A without inhibitors

Haemophilia A with anti factor VIII

Population studied

Age groups

Paediatric Population (< 18 years)

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Estimated number of subjects

215

Study design details

Setting

PedNet Registry is the largest registry in the world for pediatric patients with hemophilia. Currently, at the time of protocol amendment, 19 European countries plus Canada with approximately 32 treatment centers participate in the registry. The registry includes data for children and adolescents up to age 18 years, and with any disease severity (FVIII <25 IU/dL), which provides an adequate representation of the pediatric patient population.

The following criteria describe the population eligible for this study, which is a subset of the overall population participating in the PedNet Registry.

Inclusion criteria for inclusion in the PedNet Registry:

- Diagnosis of hemophilia A
- Factor VIII activity < 25 IU/dL
- Treated in one of the participating centers

Additional inclusion for emicizumab-specific analysis:

- Received prophylactic treatment with emicizumab

Exclusion criteria for the PedNet registry:

- Referral to a participating HTC after development of inhibitors
- Informed consent for participation in the PedNet Registry not obtained

Exclusion criteria for emicizumab-specific analysis:

- Inherited or acquired bleeding disorder other than hemophilia A
-

Outcomes

- Frequency and incidence of thromboembolic events (TEs), thrombotic microangiopathy (TMA), and anaphylaxis (including terms of systemic hypersensitivity, anaphylaxis, and anaphylactoid events), overall and in subgroups determined by age and inhibitor status, as well as by severity for patients without inhibitors.

Safety endpoints:

- Frequency and incidence of any adverse events (overall, by age, and inhibitor status).

Effectiveness endpoints (overall, by age, and inhibitor status):

- Annual bleeding rate for treated joint and major bleeds;
 - Number of treated bleeds, including soft tissue and minor bleeds;
 - Percentage of patients with zero treated bleeds.
-

Data analysis plan

The Marketing Authorisation Holder (MAH) will receive aggregate level data of patients treated with emicizumab from the PedNet Registry on an annual basis. Based on the number of patients, number of adverse events (AEs), and exposure to emicizumab provided by the PedNet Registry, the MAH will perform analyses of frequencies/incidence of AEs overall and grouped by age and inhibitor status, as well as by severity for patients without inhibitors. The youngest age group will be newborns (birth to 28 days). Other age groups include: 29 days to less than(<)6 months, 6 months-<2 years, 2 years-<6 years, 6 years-<12 years, and 12 years-18 years. The MAH will report annual bleeding rate (ABR) for treated bleeds, percentage of zero bleeds, ABR for joint bleeds and major bleeds overall and grouped by age and inhibitor status, as well as by severity for patients without inhibitors, as sent by the PedNet Registry. ABRs for soft tissue bleeds and minor bleeds is not calculated by PedNet and therefore only the number of bleeds will be presented.

Documents

Study report

[Interim_CSR,_Study_MO40685_\(PEDNET\),_PASS_Annual_Report_30Sep2020,_Published_Output-1_Redacted.pdf](#)(905.63 KB)

[MO40685 \(PEDNET\)-Interim CSR Synopsis 2, PASS Annual Report_30Sep2021_Redacted.pdf](#)(1.43 MB)

[MO40685 \(PEDNET\)-Interim CSR Synopsis 3_PASS Annual Report_28Sep2022_Redacted.pdf](#)(601.02 KB)

[MO40685 \(PEDNET\)-Interim CSR Synopsis 4_Annual Report_29-Sep-2023_Redacted.pdf](#) (629.55 KB)

Data management

Data sources

Data source(s)

PedNet Haemophilia registry

Data sources (types)

[Disease registry](#)

[Other](#)

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No